Lipodystrophy

Lipodystrophy features

• 

  Body fat changes in people with HIV: a clinical review

  This article reviews the antiretroviral side-effect of lipoatrophy (fat loss) in resource-limited settings....

  From:  HIV & AIDS treatment in practice

• 

  How frequently are ARV side-effects being seen in resource-limited settings, and how are they dealt with?

  Review of major side-effects of first-line antiretroviral regimens in resource-limited settings, and what can be done to reduce or avoid them....

  From:  HIV & AIDS treatment in practice

Lipodystrophy news from aidsmap

• The impact of older antiretrovirals on fat redistribution and cardiovascular risk factors may be irreversible

  Fat redistribution in people with HIV who have ever taken thymidine analogues and/or didanosine (TA/ddI) can persist through time, while increasing cardiovascular risk factors, according to a Danish study published in the 15 March issue of AIDS. More specifically, ...

  21 March 2019 | Alain Volny-Anne

• Integrase inhibitor treatment leads to greater weight gain

  More evidence that HIV integrase inhibitor treatment is associated with weight gain, and that people gain more weight after beginning treatment with an integrase inhibitor than people taking other drug classes, was presented this week at the Conference on ...

  07 March 2019 | Keith Alcorn

• High prevalence of diabetes and pre-diabetes in people at London HIV clinics

  Around a third of people living with HIV receiving care at three large HIV clinics in south London had diabetes or pre-diabetes, while a Liverpool HIV clinic found that 70% of patients with diabetes were not able to achieve ...

  30 November 2018 | Keith Alcorn

• Treatment with modern antiretrovirals doesn't increase the risk of hypertension

  There is no strong evidence that treatment with antiretrovirals significantly increases the risk of hypertension, investigators from the D:A:D study report in HIV Medicine. After taking into account demographic and traditional risk factors, only two older anti-HIV drugs had ...

  14 August 2018 | Michael Carter

• PrEP does not raise lipids or alter body fat, safety study finds

  Using pre-exposure prophylaxis (PrEP) does not raise lipid levels or have any substantial effect on body fat, investigators from the iPrEX trial report this month in the journal Clinical Infectious Diseases. They followed almost 500 PrEP users ...

  15 February 2018 | Keith Alcorn

• Diabetes in people with HIV over 50 overwhelmingly linked to old antiretrovirals, not age or body weight

  People with HIV over the age of 50 are more likely to have developed type 2 diabetes if they started antiretroviral treatment before 1999 or had a longer exposure to older antiretroviral drugs such as stavudine ...

  03 January 2018 | Keith Alcorn

• Lipids improved by switching from ritonavir to cobicistat as a booster for darunavir

  Switching from ritonavir to cobicistat is associated with significant improvements in cholesterol and triglyceride levels for people with dyslipidaemia, investigators from Spain report in HIV Medicine. Ritonavir was replaced with cobicistat to boost the protease inhibitor darunavir. Six months after the ...

  06 September 2017 | Michael Carter

• Switching from efavirenz to raltegravir leads to significant improvements in fatty liver disease in people with HIV

  Switching to raltegravir from efavirenz is associated with significant improvements in liver steatosis for HIV-positive people with non-alcoholic fatty liver disease, Spanish investigators report in the online edition of Clinical Infectious Diseases. The benefits of changing ...

  17 August 2017 | Michael Carter

• Non-alcoholic fatty liver disease common in people living with HIV – metabolic disorders are key risk factors

  Over a third of people with HIV have non-alcoholic fatty liver disease (NAFLD) in the absence of hepatitis B or C, according to the results of a meta-analysis and systematic review published in AIDS. Metabolic disorders ...

  12 July 2017 | Michael Carter

• High prevalence of low testosterone among younger and middle-aged ART-treated men in France

  Around one in six young and middle-aged HIV-positive men doing well on antiretroviral therapy (ART) had low testosterone levels, French investigators report in the online edition of AIDS. Overall, 12% of the sample had low testosterone, or male hypogonadism. ...

  24 January 2017 | Michael Carter

More news

Lipodystrophy news selected from other sources

• Two Experts Discuss HIV, Abdominal Fat and Body Shape Changes

  Watch TheBody.com's HIV and Aging Expert Nelson Vergel interview Dr. Stephen Grinspoon, Professor at Harvard Medical School and the Director of a Program in Nutritional Metabolism at Massachusetts General Hospital about the causes of body shape changes in HIV -- and most importantly, what you can do about them.

  24 August 2016 | The Body

• Body fat changes and lactic acidosis with HIV medicines: EMA recommends removal of class warnings for several medicines

  The European Medicines Agency (EMA) has updated the advice on the risk of body fat changes and lactic acidosis with medicines for the treatment of human immunodeficiency virus (HIV) infection. As a result, HIV medicines will no longer require a warning concerning fat redistribution in their product information, and a number of medicines of the class ‘nucleoside and nucleotide analogues’ will no longer require a warning about lactic acidosis.

  26 October 2015 | European Medicines Agency

• Abdominal Body Fat Gains on ART and Viral Load: It Matters Where You Start

  New findings show that people with higher viral loads when starting ART for the first time are more likely to undergo substantial body composition changes, such as an increased amount of fat in the abdominal area (called “central adiposity”), than those who start treatment with a lower viral load (abstract 140).

  04 March 2015 | BETA blog

• Drug that reduces abdominal fat in HIV patients also may reduce fat in liver

  The only drug to receive Food and Drug Administration approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients. Massachusetts General Hospital investigators report that six months of daily injections of tesamorelin significantly reduced fat in the liver without affecting glucose metabolism.

  19 July 2014 | Eurekalert Medicine & Health

• Unusual and rare complication described in San Francisco

  Doctors in San Francisco have reported an unusual and rare finding—an apparently harmless but disfiguring condition called cutis verticis gyrata (CVG) on the heads of four HIV-positive men. In CVG, the skin on the head becomes raised in parts and depressed in others, forming ridges and furrows.

  09 December 2013 | CATIE

• Liquid Injectable Silicone Effective, Safe for Treating HIV Patients with Facial Lipoatrophy

  Research in British Columbia, Canada, indicates that liquid injectable silicone administered properly has potential as a safe, effective, natural feeling treatment for patients with HIV-associated facial lipoatrophy (FLA). The researchers tested liquid injectable silicone because temporary filler treatments were not permanent and could result in high costs.

  04 June 2013 | Healio

• Protein Structure Discovery Could Lead to Better Treatments for HIV, Early Aging

  Researchers at the University of Virginia School of Medicine have determined the molecular structure of a protein whose mutations have been linked to several early aging diseases, and to side effects of common HIV and AIDS medications.

  11 April 2013 | University of Virginia press release

• Health Canada rejects tesamorelin for lipodystrophy

  After consideration of the NDS, Health Canada decided that the risks of tesamorelin outweighed its benefits under the proposed conditions of use.

  13 March 2013 | Theratechnologies press release

• Mark S. King: I'm Gonna Wipe That AIDS Right Off My Face

  It was all well and good to be front and center as an HIV-positive man during the first years of the AIDS crisis. It's easier being a role model when your face looks good on the poster. But then, slowly but surely, a common side effect of HIV medications, facial wasting, began to appear.

  30 January 2013 | Huffington Post

• The Bio-Alcamid disaster

  “Nightmare.” That’s how one man described a weeks-long ordeal involving ad hoc surgery, repeated infections and some hefty out-of-pocket fees – all caused by a device that was once thought to be a miracle for those dealing with the visible signs of HIV.

  08 October 2012 | Xtra

More news